Overall, this study identifies a novel oncogenic role for BCKDK in RCC, wherein it promotes tumor progression and drug resistance through AKT phosphorylation and activation of AKT‐related signaling pathways. The gene discussed is BCKDK; the disease is renal cell carcinoma.